PROF. MINNIE SARWAL, M.D., PHD
Medical Practice at Welch Rd, Palo Alto, CA
License number
California A70504
Category
Medical Practice
Type
Pediatric Nephrology
Address
Address
2
725 Welch Rd, Palo Alto, CA 94304
305 Willowbrook Dr, Menlo Park, CA 94028
305 Willowbrook Dr, Menlo Park, CA 94028
Phone
(650) 851-5268
(650) 353-1532
(650) 353-1532
Organization information
See more information about MINNIE SARWAL at bizstanding.comMinnie Sarwal MD,PHD
770 Welch Rd, Palo Alto, CA 94304
Industry:
Pediatric Kidney Care
Site:
Phone:
(650) 724-0353 (Phone)
Description:
There are 8 doctors at this site. Surgery is not performed at this site.
Minnie Menakshi Sarwal
Professional information
Minnie Sarwal, San Francisco CA
Specialties:
Pediatrics, Pediatric Nephrology, Clinical & Laboratory Immunology, Nephrology
Work:
Physician Foundation at Calif.
3700 California St, San Francisco, CA 94118 Stanford University
770 Welch Rd, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
3700 California St, San Francisco, CA 94118 Stanford University
770 Welch Rd, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
Education:
Calcutta Medical College (1987)
Dr. Minnie Sarwal - MD (Doctor of Medicine)
Hospitals:
725 Welch Rd, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
725 Welch Rd, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
725 Welch Rd, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical Schools
Calcutta National Medical College, West Bengal University Of Health Sciences
Graduated: 1987
Calcutta National Medical College, West Bengal University Of Health Sciences
Graduated: 1987
Protein And Gene Biomarkers For Rejection Of Organ Transplants
US Patent:
2013014, Jun 6, 2013
Filed:
Mar 25, 2011
Appl. No.:
13/635667
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Los Altos CA, US
Li Li - Fremont CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Stanford CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Los Altos CA, US
Li Li - Fremont CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/68, C12Q 1/68
US Classification:
506 9, 506 12
Abstract:
Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
Methods And Compositions For Determining A Graft Tolerant Phenotype In A Subject
US Patent:
2011020, Aug 18, 2011
Filed:
Aug 17, 2009
Appl. No.:
13/059745
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Li Li - Fremont CA, US
Li Li - Fremont CA, US
International Classification:
C40B 30/04, G01N 33/566, C12Q 1/68, G01N 33/573
US Classification:
506 9, 436501, 435 618, 435 616, 435 617, 435 61, 435 612, 435 71
Abstract:
Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least 5 genes in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result for the at least 5 genes. The obtained gene expression result for the at least 5 genes is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.
Biomarker Panel For Diagnosis And Prediction Of Graft Rejection
US Patent:
2012004, Feb 16, 2012
Filed:
Jan 11, 2010
Appl. No.:
13/144047
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
International Classification:
C12Q 1/68, C12M 1/34
US Classification:
435 612, 4352872
Abstract:
Methods are provided for monitoring a subject having a graft for an acute rejection (AR) response, e.g., to predict, to diagnose, and/or to characterize an AR response. In practicing the subject methods, the expression level of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is evaluated, e.g., at the nucleic acid and/or protein level, to monitor the subject. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
Compartment-Specific Non-Hla Targets For Diagnosis And Prediction Of Graft Outcome
US Patent:
2012007, Mar 29, 2012
Filed:
Feb 16, 2010
Appl. No.:
13/201838
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Atul J. Butte - Stanford CA, US
Atul J. Butte - Stanford CA, US
International Classification:
C40B 30/04, G01N 33/567, C12Q 1/68
US Classification:
506 9, 435 612, 435 721
Abstract:
Methods and composition are provided for diagnosing or predicting the status or the outcome of a graft transplant. In some embodiments, the presence or absence of one or more proteins recognizing a non-HLA/non ABO antigen is determined. The obtained result is then employed to diagnose or predict the status or outcome of the graft transplant. Also provided are compositions, systems and kits that find use in practicing the subject methods.
Methods For Monitoring Allograft Rejection
US Patent:
2012016, Jun 28, 2012
Filed:
Feb 12, 2010
Appl. No.:
13/148458
Inventors:
Atul J. Butte - Stanford CA, US
Rong Chen - Fremont CA, US
Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Rong Chen - Fremont CA, US
Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/566, C40B 30/04
US Classification:
506 9, 435 792, 435 71, 435 721
Abstract:
Methods are provided for monitoring an allograft recipient for a rejection response, e.g., to predict, to diagnose, and/or to characterize a rejection response. In practicing the subject methods, the level of at least one protein in a sample from the allograft recipient, e.g., serum, urine, blood, CSF, tears or saliva, is evaluated, to monitor the subject. Also provided are compositions, systems, and kits that find use in practicing the subject methods.
Biomarkers For The Diagnosis Of Kidney Graft Rejection
US Patent:
2012028, Nov 8, 2012
Filed:
Nov 24, 2010
Appl. No.:
13/508013
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Bruce Xuefeng Ling - Palo alto CA, US
Tara Sigdel - Palo Alto CA, US
James Schilling - San Mateo CA, US
Bruce Xuefeng Ling - Palo alto CA, US
Tara Sigdel - Palo Alto CA, US
James Schilling - San Mateo CA, US
International Classification:
G01N 27/72, C40B 30/04, C40B 40/06, C12Q 1/68
US Classification:
506 9, 435 612, 436 86, 506 16
Abstract:
Methods are provided for determining a transplant category of a subject having a kidney graft. In practicing one aspect of the subject methods, the peptide signature of a non-invasive sample derived from the transplant subject (e.g., a urine sample) is used to determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK virus nephropathy (BK), and the like). In other embodiments, a gene expression signature from a biopsy sample from the subject (e.g., mRNA level) is used to determine the subject's transplant category. In certain embodiments both a peptide signature and a gene expression signature are used. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
Biomarkers For Determining An Allograft Tolerant Phenotype
US Patent:
2012032, Dec 27, 2012
Filed:
Dec 1, 2010
Appl. No.:
13/512539
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Li Li - Fremont CA, US
Samuel Strober - Stanford CA, US
Li Li - Fremont CA, US
Samuel Strober - Stanford CA, US
International Classification:
C40B 30/04, C40B 40/06, C40B 40/10, C12Q 1/68
US Classification:
506 9, 435 611, 435 612, 506 16, 506 18, 435 792, 436501
Abstract:
Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression level of one or more gene in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result, where the gene expression result includes a result for a biomarker of graft tolerance. The obtained gene expression result is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.
Antibody Biomarkers For Diabetes
US Patent:
2014005, Feb 20, 2014
Filed:
Apr 6, 2012
Appl. No.:
14/001825
Inventors:
Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Tara Sigdel - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junio University - Palo Alto
International Classification:
G01N 33/68
US Classification:
506 9, 436501, 435 792, 506 18
Abstract:
Methods are provided for determining whether a subject has a diabetes phenotype. In practicing the subject methods, a sample, e.g., a blood sample, from a subject is analyzed for the presence of one or more autoantibodies to obtain an antibody signature. The obtained antibody signature is then employed to determine whether the subject has a diabetes phenotype. The subject methods may be used in diagnostic or prognostic applications, e.g., determining whether the subject has diabetes (e.g., T1D or T2D), or monitoring a subject with diabetes to determine whether the subject has or will develop ESRD. Also provided are compositions, systems and kits that find use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the diagnosis and monitoring of diabetes in a subject.